Replimune (REPL) CCO sells 12,000 shares under 10b5-1 plan

Rhea-AI Filing Summary

Replimune Group Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock in an open-market transaction. The sale occurred on June 1, 2026 at a weighted average price of $9.24 per share, with individual trade prices ranging from $9.15 to $9.62 per share.

After this transaction, Sarchi directly holds 180,962 Replimune shares. The filing notes that the sale was executed under a pre-arranged trading plan adopted on December 15, 2025 intended to comply with Rule 10b5-1(c), indicating it was scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 12,000 shares ($110,880)

Net Sell 1 txn

Insider Sarchi Christopher

Role Chief Commercial Officer

Sold 12,000 shs ($111K)

Type	Security	Shares	Price	Value
Sale	Common Stock	12,000	$9.24	$111K

Holdings After Transaction: Common Stock — 180,962 shares (Direct, null)

Footnotes (1)

1. The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $9.15 to $9.62 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

Key Figures

Shares sold: 12,000 shares Average sale price: $9.24 per share Post-transaction holdings: 180,962 shares +2 more

5 metrics

Shares sold 12,000 shares Open-market sale on June 1, 2026

Average sale price $9.24 per share Weighted average price for 12,000 shares sold

Post-transaction holdings 180,962 shares Shares directly held after June 1, 2026 sale

Sale price range $9.15–$9.62 per share Range of prices for multiple sale transactions

10b5-1 plan adoption date December 15, 2025 Date trading plan was adopted

Key Terms

Rule 10b5-1(c), trading plan, weighted average price, open-market sale, +1 more

5 terms

Rule 10b5-1(c) regulatory

"intended to comply with Rule 10b5-1(c) under the Securities Exchange Act"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

trading plan financial

"The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan"

A trading plan is a written set of rules an investor follows about what to buy or sell, when to enter and exit positions, and how much risk to accept—like a travel itinerary that maps the route, stops, and budget before a trip. It matters because it helps remove emotional decisions during market swings, enforces discipline, and makes performance easier to review and improve, reducing the chance of costly impulsive moves.

weighted average price financial

"The price reported reflects a weighted average price of the Shares."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"The sales reported on this Form 4 were made by the Reporting Person"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sarchi Christopher

(Last) (First) (Middle)

C/O REPLIMUNE GROUP, INC.

500 UNICORN PARK DRIVE, SUITE 303

(Street)

WOBURN MASSACHUSETTS 01801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Replimune Group, Inc. [ REPL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		12,000(1)	D	$9.24(2)	180,962	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 15, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

2. The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $9.15 to $9.62 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

	/s/ Shawn Glidden, attorney-in-fact	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Replimune (REPL) disclose in this Form 4?

Replimune disclosed that Chief Commercial Officer Christopher Sarchi sold 12,000 shares of common stock. The open-market sale occurred on June 1, 2026 at a weighted average price of $9.24 per share.

At what price did Replimune CCO Christopher Sarchi sell his REPL shares?

Christopher Sarchi sold 12,000 Replimune shares at a weighted average price of $9.24. Individual trades were executed between $9.15 and $9.62 per share, according to the Form 4 footnotes.

How many Replimune (REPL) shares does the insider hold after this sale?

Following the June 1, 2026 sale, Christopher Sarchi directly holds 180,962 Replimune common shares. This post-transaction balance is disclosed in the Form 4 as his remaining ownership position.

Was the Replimune insider sale made under a Rule 10b5-1 trading plan?

Yes. The Form 4 states the sale was made under a trading plan adopted December 15, 2025 and intended to comply with Rule 10b5-1(c), indicating the trades were pre-scheduled.

What is the total size of the Replimune CCO’s recent share sale?

The recent Replimune transaction by Chief Commercial Officer Christopher Sarchi involved selling 12,000 shares of common stock. All were sold in open-market trades within the stated price range.